Viridian Therapeutics Stock Forecast

Stock Price Forecast

According to 17 analysts polled by S&P Global, Viridian Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $33.94. The average 1-year stock price forecast is 96.41% higher than the current stock price, while the lowest is $20 (+15.74%) and the highest is $50 (+189.35%).

Price Target: $33.94 (+96.41%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$20	$33.94	$34.5	$50
Change	+15.74%	+96.41%	+99.65%	+189.35%

Analyst Ratings

The average analyst rating for Viridian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	14	14	14	13	13	13
Buy	3	3	3	3	3	3
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	18	18	18	17	17	17

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Derek Archila Wells Fargo	Wells Fargo	Hold Maintains $35 → $20	Hold	Maintains	$35 → $20	+15.74%	Jun 17, 2026
Richard Law CFA Goldman Sachs	Goldman Sachs	Buy Maintains $31 → $35	Buy	Maintains	$31 → $35	+102.55%	Jun 11, 2026
Gavin Clark-Gartner Evercore ISI	Evercore ISI	Buy Maintains $27 → $26	Buy	Maintains	$27 → $26	+50.46%	May 15, 2026
Alex Thompson CFA Stifel Nicolaus	Stifel Nicolaus	Buy Maintains $48 → $39	Buy	Maintains	$48 → $39	+125.69%	May 13, 2026
Rami Katkhuda LifeSci Capital	LifeSci Capital	Buy Maintains $35	Buy	Maintains	$35	+102.55%	May 10, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

33.62M

from 70.85M

-52.55%

from 70.85M

Revenue Next Year

244.44M

from 33.62M

627.09%

from 33.62M

EPS This Year

-3.81

from -3.32

EPS Next Year

-2.51

from -3.81

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	2.96M	1.77M	314.00K	302.00K	70.85M	33.62M
Revenue Growth	182.19%	-40.20%	-82.28%	-3.82%	23,359.93%	-52.55%
Gross Profit	-53.92M	-99.12M	-159.45M	-237.95M	-268.08M	28.97M
Gross Margin	-1,819.88%	-5,593.79%	-50,780.57%	-78,792.05%	-378.38%	86.16%
Operating Income	-79.73M	-134.30M	-254.45M	-299.04M	-363.40M	-456.03M
Net Income	-79.41M	-129.87M	-237.73M	-269.95M	-342.60M	-438.26M
EPS	-	-	-	-	-3.32	-3.81
Free Cash Flow	-33.91M	-48.83M	-102.50M	-136.29M	-162.07M	-292.93M
No. Analysts	-	-	-	-	-	13

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	66.2M
Avg	33.6M
Low	10.1M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-6.6%
Avg	-52.5%
Low	-85.7%

EPS Forecast

EPS	2026	2027	2028
High	-3.21
Avg	-3.81
Low	-4.54

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-